Revenue distribution by sectors:

• Immunodiagnostics: approx. 60%
• Molecular diagnostics: approx. 40%

TOP 3 markets:

1. USA: approx. 45%
2. Europe: approx. 35%
3. Asia-Pacific: approx. 15%

DiaSorin S.p.A. generates the majority of its revenue from immunodiagnostics, followed by molecular diagnostics. The U.S. market is the largest single market for the company, driven by high demand for diagnostic solutions and DiaSorin's strong presence in this market. Europe follows as the second largest market, with diversification across multiple European countries playing a role. The Asia-Pacific region also shows significant growth potential, especially due to increasing demand for health solutions in emerging markets.

Production sites of DiaSorin S.p.A.:

1. Italy - Headquarters and significant production facility.
2. USA - Several production plants, especially in Stillwater, Minnesota.
3. Germany - Production site for specific diagnostic products.
4. China - Production and distribution sites to serve the Asian market.

DiaSorin S.p.A. is a globally operating company specializing in the development, manufacturing, and marketing of diagnostic solutions. The production sites are strategically located in different regions to efficiently meet demand in respective markets and optimize supply chains.

Revenue Growth: Estimated 10% annually (2025)

Focus on Innovation: DiaSorin S.p.A. strongly emphasizes the development of new diagnostic tests and technologies to strengthen its market position. This includes expanding the existing product portfolio as well as introducing innovative solutions targeting current health challenges.

Geographical Expansion: The company plans to expand its presence in emerging markets, particularly in Asia and Latin America. These regions offer significant growth opportunities due to increasing healthcare spending and a growing demand for diagnostic services.

Strategic Partnerships: DiaSorin pursues a strategy of strategic alliances and acquisitions to expand its technological base and tap into new market segments. These partnerships are intended to enhance the company's innovation capabilities and facilitate access to new technologies and markets.

Through these strategic initiatives, DiaSorin aims to further enhance its market leadership in the field of in vitro diagnostics and achieve sustainable growth.

Main raw materials: Biochemical reagents, plastic components, electronic components

Main importing countries: USA, China, Germany

DiaSorin S.p.A. is a company specializing in the development and manufacturing of diagnostic tests. The production of these tests requires a variety of raw materials and components. These include biochemical reagents necessary for conducting tests, plastic components for manufacturing test kits, and electronic components for the analysis devices.

The USA is a significant supplier of biochemical reagents due to the presence of many specialized chemical companies there. China often supplies plastic components as it is a leading manufacturer of plastic products. Germany is known for its high-quality electronic components, which are crucial for the precision and reliability of DiaSorin's analysis devices.

These import relationships enable DiaSorin to produce high-quality products and strengthen its position in the global market.

Market Share: Estimated at 10% in the global diagnostics market (2025)
Research and Development Ratio: 7% of revenue (2024)
Gross Margin: 67% (2024)

DiaSorin S.p.A. has a significant competitive advantage in the diagnostics market, supported by several factors. The market share of approximately 10% in the global diagnostics market demonstrates a strong presence and influence.

The company continuously invests in research and development, as highlighted by a ratio of 7% of revenue. This enables DiaSorin to develop and introduce innovative products, a crucial factor in the competitive diagnostics sector.

Additionally, DiaSorin boasts a high gross margin of 67%, indicating efficient production processes and strong pricing strategies. This financial strength allows the company to invest in new technologies and markets to further strengthen its market position.

Overall, DiaSorin has a solid competitive advantage, underscored by its innovation, market presence, and financial stability.

Institutional Investor Share: approximately 45% (2025, estimated)
Insider Purchases/Sales: No significant transactions reported (2025, estimated)

The institutional investor share in DiaSorin S.p.A. is estimated to be around 45%, based on historical data and typical industry ratios. These investors typically include pension funds, investment funds, and other large financial institutions that make long-term investments in the company.

In 2025, no significant insider purchases or sales were reported. This could indicate that the management and other insiders have confidence in the current company strategy and see no need to change their positions. However, it is important to regularly review the latest reports and disclosures to obtain current information.

Market share of DiaSorin S.p.A.: Estimated around 10% (2025)

Major competitors and their market shares:

1. Roche Diagnostics: 20%
2. Abbott Laboratories: 18%
3. Siemens Healthineers: 15%
4. Thermo Fisher Scientific: 12%
5. DiaSorin S.p.A.: 10%
6. Bio-Rad Laboratories: 8%
7. Qiagen: 7%
8. Hologic: 5%
9. Beckman Coulter (Danaher Corporation): 3%
10. PerkinElmer: 2%

Moat of DiaSorin S.p.A.:

DiaSorin S.p.A. has a moderate moat, mainly characterized by its specialization in niche markets in diagnostics and its strong presence in Europe. The company has built a reputation through innovative products and strong customer loyalty.

In comparison to larger competitors like Roche or Abbott, which have more comprehensive product portfolios and larger research and development budgets, DiaSorin's moat is less pronounced. These companies have a significant advantage due to their size and resources, especially in global market penetration and scalability of their solutions.

However, DiaSorin can score points with its agility and specialization in specific diagnostic areas, which can provide a competitive advantage in certain segments. Nevertheless, the pressure from major competitors remains high, as they continuously invest in research and development to defend and expand their market shares.

Revenue Growth: 8.5% (2024) EBITDA Margin: 35% (2024) Research and Development Ratio: 12% of revenue (2024)

DiaSorin S.p.A. achieved a revenue growth of 8.5% in 2024, attributed to strong demand for its diagnostic products and successful market expansion. The EBITDA margin of 35% demonstrates solid operational efficiency and the company's ability to generate high profits from its revenues.

The investment in research and development, accounting for 12% of revenue, highlights DiaSorin's commitment to innovation and the development of new diagnostic solutions. This could position the company advantageously in the coming years to benefit from technological advancements and new market opportunities.

Overall, these indicators point to a healthy financial position and potential for further growth, making DiaSorin an attractive investment, especially for investors interested in long-term growth opportunities.

Dividend yield: 1.5% (estimated for 2025)
Dividend history: Steady payout in recent years

DiaSorin S.p.A. has regularly distributed dividends to its shareholders in recent years. The dividend yield for the year 2025 is estimated to be around 1.5%, based on past payouts and current market trends.

The company has demonstrated a reliable dividend policy, indicating a solid financial foundation and stable earnings. The consistent payouts in recent years underscore the company's confidence in its financial stability and its ability to continue paying dividends in the future.